#SFHS2604988ADecree on Pharmaceutical Specialty Coverage - March 2026
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This decree outlines the coverage for a specific pharmaceutical specialty, Dalbavancin, under the French healthcare system. It provides guidelines on which patients are eligible for reimbursement based on the severity and etiology of their bacterial skin infections. The coverage is limited to adult patients with confirmed or suspected staphylococcal infections resistant to methicillin.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Establishment of coverage criteria for Dalbavancin.
- Limitation of reimbursement to specific adult patients.
- Inclusion of requirements regarding infection severity and bacterial resistance.
Obligations
What this law requires
Reimburse Dalbavancin (UCD code 3400890039956, 500mg) when prescribed for acute bacterial skin and soft tissue infections in adult patients with confirmed or suspected methicillin-resistant staphylococcal infection of significant severity
Limit Dalbavancin coverage exclusively to the therapeutic indication of acute bacterial skin and soft tissue infections (IBAPTM) in adults with confirmed or suspected methicillin-resistant staphylococcal etiology
Eliminate patient co-payments (participation de l'assuré) for Dalbavancin when prescribed within the approved therapeutic indication
Only provide reimbursement for Dalbavancin to adult patients; pediatric patients are excluded from coverage
Require confirmation or strong suspicion of methicillin resistance before authorizing Dalbavancin reimbursement